Viridian's drug cuts thyroid eye disease symptoms in late-stage study
Shares rise 14% as drug meets main and secondary goals
Analysts highlight less frequent dosing as a key advantage
Jefferies estimates potential peak sales of $2 billion
Adds analyst comment in paragraphs 3-5 and paragraph 9, background on disease throughout
By Mariam Sunny
Sept 10 (Reuters) -Viridian Therapeutics VRDN.O said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first rival to Amgen's blockbuster therapy Tepezza.
Shares of the company rose 14% to $16.19 in morning trading as the drug met the trial's main and secondary goals in patients with the rare disorder that is estimated to affect between 90 and 300 per 100,000 people in the U.S.
Wall Street analysts said the need for less frequent dosing for Viridian's drug, veligrotug, versus Amgen's could make it a convenient alternative.
"Today's data looks very good and promising with the potential for a shorter-duration and more convenient alternative to Tepezza and a good side effect profile," Jefferies analyst Michael Yee said in an emailed response.
Yee estimates potential peak sales of $2 billion for Viridian's drug as a treatment for TED. Tepezza generated sales of $479 million in the three months ended June 30. Amgen had gained the drug through its $27.8 billion deal for Horizon Therapeutics.
TED causes inflammation and damage to the tissues around the eye and usually occurs in people with Graves' disease, an immune system disorder that results in overproduction of thyroid hormones.
Veligrotug helped 64% of patients, when adjusted for placebo rates, achieve at least a 2-millimeter reduction in eye bulging after 15 weeks of treatment, Viridian said.
The company said 5.5% of patients, when adjusted for placebo rates, in the 113-member study experienced treatment-related hearing impairment. The hearing-impairment was below its expectations, it added.
Truist analyst Srikripa Devarakonda said while the Viridian drug was effective, the hearing loss side effect left room for future rivals.
Viridian expects data from a second late-stage study toward the end of the year and plans to apply for approval in the second half of 2025.
Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar, Anil D'Silva and Sriraj Kalluvila
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
